Reduction of Myocardial Ischemia-Reperfusion Injury by Inhibiting Interleukin-1 Alpha

Journal of Cardiovascular Pharmacology

Volumn 69, Issue 3, 2017, Pages 156-160

  Mauro, Adolfo G ^a,b   Mezzaroma, Eleonora ^a   Torrado, Juan ^a   Kundur, Priyanka ^a   Joshi, Priyashma ^a   Stroud, Kelsey ^a   Quaini, Federico ^b   Lagrasta, Costanza A ^b   Abbate, Antonio ^a   Toldo, Stefano ^a,c  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b UNIVERSITY OF PARMA   (Italy)

^c VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Inflammation; Injury; Interleukin 1; Ischemia; Reperfusion

Indexed keywords

AB 400NA; BLOCKING ANTIBODY; INFLAMMASOME; INTERLEUKIN 1 ANTIBODY; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA CONVERTING ENZYME; POLYCLONAL ANTIBODY; PROTECTIVE AGENT; TROPONIN I; UNCLASSIFIED DRUG; IMMUNOLOGIC FACTOR;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; ENZYME ACTIVITY; HEART INFARCTION SIZE; HEART LEFT VENTRICLE FUNCTION; HEART PROTECTION; LEFT ANTERIOR DESCENDING CORONARY ARTERY; LEFT VENTRICULAR FRACTIONAL SHORTENING; MALE; MOUSE; MYOCARDIAL ISCHEMIA REPERFUSION INJURY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRANSTHORACIC ECHOCARDIOGRAPHY; ANIMAL; ANTAGONISTS AND INHIBITORS; DIAGNOSTIC IMAGING; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM; RANDOMIZATION;

ANIMALS; IMMUNOLOGIC FACTORS; INTERLEUKIN-1ALPHA; MALE; MICE; MICE, INBRED ICR; MYOCARDIAL REPERFUSION INJURY; RANDOM ALLOCATION;

EID: 85016115577     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000452     Document Type: Article

References (32)

1. Frangogiannis NG. Inflammation in cardiac injury, repair and regeneration. Curr Opin Cardiol. 2015;30:240-245.
2. Bertheloot D, Latz E. HMGB1, IL-1a, IL-33 and S100 proteins: dualfunction alarmins. Cell Mol Immunol. 2017;14:43-64.
3. Rider P, Carmi Y, Guttman O, et al. IL-1a and IL-1b recruit different myeloid cells and promote different stages of sterile inflammation. J Immunol. 2011;187:4835-4843.
4. Cohen I, Rider P, Vornov E, et al. IL-1a is a DNA damage sensor linking genotoxic stress signaling to sterile inflammation and innate immunity. Sci Rep. 2015;5:14756.
5. Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood. 2011;117:3720-3732.
6. Toldo S, Mezzaroma E, Mauro AG, et al. The inflammasome in myocardial injury and cardiac remodeling. Antioxid Redox Signal. 2015;22:1146-1161.
7. Mezzaroma E, Toldo S, Abbate A. Role of NLRP3 (cryopyrin) in acute myocardial infarction. Cardiovasc Res. 2013;99:225-226.
8. Toldo S, Seropian IM, Mezzaroma E, et al. Alpha-1 antitrypsin inhibits caspase-1 and protects from acute myocardial ischemia-reperfusion injury. J Mol Cell Cardiol. 2011;51:244-251.
9. Toldo S, Breckenridge DG, Mezzaroma E, et al. Inhibition of apoptosis signal-regulating kinase 1 reduces myocardial ischemia-reperfusion injury in the mouse. J Am Heart Assoc. 2012;1:e002360.
10. Bersudsky M, Luski L, Fishman D, et al. Non-redundant properties of IL-1a and IL-1b during acute colon inflammation in mice. Gut. 2014;63: 598-609.
11. Mezzaroma E, Toldo S, Farkas D, et al. The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse. Proc Natl Acad Sci USA. 2011;108:19725-19730.
12. Abbate A, Salloum FN, Vecile E, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. Circulation. 2008;117:2670-2683.
13. Seropian IM, Abbate A, Toldo S, et al. Pharmacologic inhibition of phosphoinositide 3-kinase gamma (PI3Kg) promotes infarct resorption and prevents adverse cardiac remodeling after myocardial infarction in mice. J Cardiovasc Pharmacol. 2010;56:651-658.
14. Ibáñez B, Heusch G, Ovize M, et al. Evolving therapies for myocardial ischemia/reperfusion injury. J Am Coll Cardiol. 2015;65:1454-1471.
15. Piper H, Abdallah Y, Schäfer C. The first minutes of reperfusion: a window of opportunity for cardioprotection. Cardiovasc Res. 2004; 61:365-371.
16. Marchetti C, Chojnacki J, Toldo S, et al. A novel pharmacologic inhibitor of the NLRP3 inflammasome limits myocardial injury after ischemiareperfusion in the mouse. J Cardiovasc Pharmacol. 2014;63:316-322.
17. Toldo S, Marchetti C, Mauro AG, et al. Inhibition of the NLRP3 inflammasome limits the inflammatory injury following myocardial ischemiareperfusion in the mouse. Int J Cardiol. 2016;209:215-220.
18. Van Hout GP, Bosch L, Ellenbroek GH, et al. The selective NLRP3-inflammasome inhibitor MCC950 reduces infarct size and preserves cardiac function in a pig model of myocardial infarction. Eur Heart J. 2016. doi: 10. 1093/eurheartj/ehw247.
19. Frangogiannis NG. Regulation of the inflammatory response in cardiac repair. Circ Res. 2012;110:159-173.
20. Sager HB, Heidt T, Hulsmans M, et al. Targeting interleukin-1 reduces leukocyte production after acute myocardial infarction. Circulation. 2015;132:1880-1890.
21. Van Tassell BW, Toldo S, Mezzaroma E, et al. Targeting interleukin-1 in heart disease. Circulation. 2013;128:1910-1923.
22. Toldo S, Mezzaroma E, O'Brien L, et al. Interleukin-18 mediates interleukin-1-induced cardiac dysfunction. Am J Physiol Heart Circ Physiol. 2014;306:H1025-H1031.
23. Marchetti C, Toldo S, Chojnacki J, et al. Pharmacologic inhibition of the NLRP3 inflammasome preserves cardiac function after ischemic and nonischemic injury in the mouse. J Cardiovasc Pharmacol. 2015;66:1-8.
24. Syed FM, Hahn HS, Odley A, et al. Proapoptotic effects of caspase-1/interleukin-converting enzyme dominate in myocardial ischemia. Circ Res. 2005;96:1103-1109.
25. Merkle S, Frantz S, Schön MP, et al. A role for caspase-1 in heart failure. Circ Res. 2007;100:645-653.
26. Toldo S, Mezzaroma E, Van Tassell BW, et al. Interleukin-1beta blockade improves cardiac remodelling after myocardial infarction without interrupting the inflammasome in the mouse. Exp Physiol. 2013;98: 734-745.
27. Bujak M, Frangogiannis NG. The role of IL-1 in the pathogenesis of heart disease. Arch Immunol Ther Exp (Warsz). 2009;57:165-176.
28. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol. 2007;81:1-5.
29. Neuhof C, Neuhof H. Calpain system and its involvement in myocardial ischemia and reperfusion injury. World J Cardiol. 2014;6:638-652.
30. Inserte J, Hernando V, Garcia-Dorado D. Contribution of calpains to myocardial ischaemia/reperfusion injury. Cardiovasc Res. 2012;96: 23-31.
31. Lugrin J, Parapanov R, Rosenblatt-Velin N, et al. Cutting edge: IL-1a is a crucial danger signal triggering acute myocardial inflammation during myocardial infarction. J Immunol. 2015;194:499-503.
32. Abbate A, Van Tassell BW, Seropian IM, et al. Interleukin-1beta modulation using a genetically engineered antibody prevents adverse cardiac remodelling following acute myocardial infarction in the mouse. Eur J Heart Fail. 2010;12:319-322.